

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10,575,049
				Filing Date	April 5, 2006
				First Named Inventor	David De Kretser
				Art Unit	1644
				Examiner Name	Maher M. Haddad
Sheet	1	of	3	Attorney Docket Number	PARA003US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		URBANEK et al., "Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin," <i>PNAS USA</i> , 96:8573-78 (1999).	
		PHILLIPS & WOODRUFF, "Inhibin: actions and signaling," <i>Growth factors</i> , 22:13-18 (2004).	
		DE KRETSER, et al., "Inhibins, activins and follistatin in reproduction," <i>Human reproduction update</i> , 8:529-41 (2002)	
		MATZUK, et al., "Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice," <i>PNAS USA</i> , 91:8817-21 (1994).	
		MATZUK, et al., "Multiple defects and perinatal death in mice deficient in follistatin," <i>Nature</i> , 374:360-63 (1995)	
		BILEZIKIAN, et al., "Pituitary actions of ligands of the TGF-β family: activins and inhibins," <i>Reproduction</i> , 132:207-15 (2006)	
		SHIMONAKA, et al., "Follistatin binds to both activin and inhibin through the common beta-subunit," <i>Endocrinology</i> , 128:3313-15 (1991)	
		ALEMAN-MUENCH & SOLDEVILA, "When versatility matters: activins/inhibins as key regulators of immunity," <i>Immunology and cell biology</i> , In press (2011)	
		LICONA-LIMÓN, et al., "Activins and inhibins: novel regulators of thymocyte development," <i>Biochemical and biophysical research communications</i> , 381:229-35 (2009)	
		BROXMEYER, et al., "Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin," <i>PNAS USA</i> , 85:9052-56 (1988)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10,575,049
		Filing Date	April 5, 2006
		First Named Inventor	David De Kretser
		Art Unit	1644
		Examiner Name	Maher M. Haddad
(Use as many sheets as necessary)			
Sheet	2	of	3
		Attorney Docket Number	
		PARA003US	

## NON-PATENT LITERATURE DOCUMENTS

EXAMINER ATTACHED DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		JONES, et al., "Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia," <i>PNAS USA</i> , 104:16239-44 (2007)
		PATELLA, et al., "Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis," <i>American journal of physiology: Gastrointestinal and liver physiology</i> , 290:G137-44 (2006)
		BOEHM, "Design principle of adaptive immune systems," <i>Nature Reviews. Immunology</i> , 11:307-17 (2011)
		BENABDALLAH, et al., "Overexpression of follistatin in human myoblasts increases their proliferation and differentiation, and improves the graft success in SCID mice," <i>Cell transplantation</i> , 18:709-18 (2009)
		KANAMOTO, et al., "Beneficial effects of follistatin in hepatic ischemia-reperfusion injuries in rats," <i>Digestive diseases and sciences</i> , 56:1075-81 (2011)
		LARSON, et al., "Scarless fetal wound healing: a basic science review," <i>Plastic and reconstructive surgery</i> , 126:1172-80 (2010)
		MUKHERJEE, et al., "FSTL3 deletion reveals roles for TGF- $\beta$ family ligands in bludose and fat homeostasis in adults," <i>PNAS USA</i> , 104(4):1348-53 (2007)
		SIDIS, et al., "Biological activity of Follistatin Isoforms and FSTL-3 is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin and BMPs," <i>Endocrinology</i> , 147(7)3586-97 (2006)

Examiner Signature	/Maher Haddad/	Date Considered	09/15/2011
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/